Table 2 Efficacy evaluation

From: Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

 

Total (n = 47, %)

Chemo-free (n = 9, %)

Chemo (n = 38, %)

MTD pre, mm, median [IQR] a

21.4 [12.5, 32.5]

21.4 [15.0, 32.0]

21.2 [12.0, 32.7]

PLN pre, median [IQR] a

0.0 [0.0, 1.0]

1.0 [0.0, 2.0]

0.0 [0.0, 1.0]

cTNM stage following induction therapy

0/I

18 (38.3)

2 (22.2)

16 (42.1)

II

11 (23.4)

3 (33.3)

8 (21.1)

III

18 (38.3)

4 (44.4)

14 (36.8)

MTD post, mm, median [IQR] a

20.0 [0.0, 30.0]

21.0 [0.0, 32.0]

19.5 [0.0, 29.5]

PLN post, median [IQR] a

0.0 [0.0, 1.5]

1.0 [0.0, 2.0]

0.0 [0.0, 1.0]

ypN downstaging

37 (78.7)

6 (66.7)

31 (81.6)

ypTNM

0/I

27 (57.4)

4 (44.4)

23 (60.5)

II

6 (12.8)

1 (4.8)

5 (13.2)

III

14 (29.8)

4 (44.4)

10 (26.3)

Residual tumor cell, % (range)

19.0 (0.0-90.0)

24.4 (0.0-80.0)

20.0 (0.0-90.0)

Pathologic regression

pCR a

18 (38.3)

3 (33.3)

15 (39.5)

MPR a

29 (61.7)

5 (55.6)

24 (63.2)

  1. aMTD pre maximum tumor dimension measured prior to surgery following induction therapy, MTD post maximum tumor dimension based on the surgical pathological report following induction therapy, PLN pre positive lymph node number prior to surgery following induction therapy, PLN post the number of positive lymph nodes based on the surgical pathological report following induction therapy, IQR interquartile range, pCR pathological complete response, MPR major pathological response.
Back to article page